pharmaphorum

JULY 25, 2022

The new drug is one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab, along with talquetamab which binds to CD3 and GPRC5D.

Antibody 52

Antibody Medicine Drugs Trials 52

pharmaphorum

FEBRUARY 16, 2021

In this first draft guidance NICE raised a series of issues with Zynteglo, which bluebird has already agreed to supply at a confidential discount from its hefty price tag, which is around €1.57 million in Europe. NICE said that data came from a small sample of patients and is using its standard discount rate of 3.5%

Gene Therapy 72

Gene Therapy Gene Medicine Development 72

XTalks

JANUARY 19, 2024

Late sequela could include pneumonitis, lung fibrosis, fertility disorders and secondary malignancies. This biological variability adds complexity, but with that complexity comes the power to choose the targets, the tags and the payloads and select combinations appropriate to the patient to personalize that therapy.

DNA 66

DNA Radiology FDA Approval Development 66